Sugar-Sweetened Beverages and Cancer Risk: A Narrative Review.

Cancer continues to be a major public health challenge worldwide, not only for being one of the leading causes of death but also because the number of incident cases is projected to grow in the next decades. Meanwhile, sugar-sweetened beverages (SSB) consumption has risen since the past century and constitutes a considerable fraction of added sugars in daily diet. Several studies have analyzed the relationship between SSB intake and health and found substantial evidence for effects on obesity, type 2 diabetes and metabolic syndrome.

Explaining the increment in coronary heart disease mortality in Mexico between 2000 and 2012.

Background: Mexico is still in the growing phase of the epidemic of coronary heart disease (CHD), with mortality increasing by 48% since 1980. However, no studies have analyzed the drivers of these trends. We aimed to model CHD deaths between 2000 and 2012 in Mexico and to quantify the proportion of the mortality change attributable to advances in medical treatments and to changes in population-wide cardiovascular risk factors.

Factors associated with healthy aging in septuagenarian and nonagenarian Mexican adults.

Objective: To examine the factors associated with healthy aging in a cohort of Mexican adults after a follow-up of 14 years.

Study Design: Participants were part of a prospective cohort of the Mexican Healthy Aging Study (MHAS), from which we included 5142 individuals aged 63 years or more.

Main Outcome: Healthy aging, defined as reaching age 77 or 90 without major chronic conditions or physical limitations.

Longitudinal associations between blood lead concentrations lower than 10 microg/dL and neurobehavioral development in environmentally exposed children in Mexico City.

Objective: Increasing evidence suggests that 10 microg/dL, the current Centers for Disease Control and Prevention screening guideline for children's blood lead level, should not be interpreted as a level at which adverse effects do not occur. Using data from a prospective study conducted in Mexico City, Mexico, we evaluated the dose-effect relationship between blood lead levels and neurodevelopment at 12 and 24 months of age.

Methods: The study population consisted of 294 children whose blood lead levels at both 12 and 24 months of age were < 10 microg/dL; blood lead levels were measured by graphite furnace atomic absorption spectroscopy; Bayley Scales of Infant Development II were administered at these ages.